BEGIN:VCALENDAR
PRODID:-//github.com/ical-org/ical.net//NONSGML ical.net 5.1.4//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:  Jonathan Aning is a Consultant Urological Surgeon at the Bri
 stol Urological Institute (BUI) and a Honorary Professor of Urological Onc
 ology at the University of Bristol. He trained in Urology in the South Wes
 t of England.  After completing the Uro-oncology fellowship at the Depart
 ment of Urological Sciences\, University of British Columbia\, Vancouver\,
  Canada\, he spent 4 years as a Consultant Urological Surgeon at the Freem
 an Hospital\, Newcastle upon Tyne (2014-2018).  Jonathan was appointed to
  the Bristol Urological Institute (BUI)\, North Bristol NHS Trust in 2018.
  He specialises in the management of prostate and bladder cancer including
  robotic surgery and leads the uro-oncology research program at the BUI. 
  Jonathan is passionate about improving patient outcomes and has active re
 search interests across the patient pathway in prostate and bladder cancer
 . He is the present Chair of the Somerset\, Wiltshire\, Avon and Glouceste
 rshire (SWAG) Urology Cancer Clinical Advisory Group\, the Clinical Lead f
 or Cancer Genomics Research for the South West Genomic Medicine Service Al
 liance and serves as a member of the European Association of Urology (EAU)
  Section of Oncological Urology Board. He has previously served as the cha
 ir of the British Association of Urology (BAUS) Section of Oncology. 
DTEND:20270210T083000Z
DTSTAMP:20261031T105025Z
DTSTART:20270210T070000Z
LOCATION:
SEQUENCE:1
SUMMARY:Speaker: ProfessorJonathan Aning - Prostate Cancer
UID:e0c04b67-3b83-4ea7-a130-50b9fdc16d24
X-ALT-DESC;FMTTYPE=text/html:<p>&nbsp\;</p>\n\n<p style="box-sizing: border
 -box\; margin: 0px 0px 0.75rem\; color: rgb(35\, 31\, 32)\; font-family: &
 quot\;Helvetica Neue&quot\;\, Helvetica\, Arial\, sans-serif\; font-size: 
 16px\;">Jonathan Aning is a Consultant Urological Surgeon at the Bristol U
 rological Institute (BUI) and a Honorary Professor of Urological Oncology 
 at the University of Bristol.</p>\n\n<p style="box-sizing: border-box\; ma
 rgin: 0px 0px 0.75rem\; color: rgb(35\, 31\, 32)\; font-family: &quot\;Hel
 vetica Neue&quot\;\, Helvetica\, Arial\, sans-serif\; font-size: 16px\;">H
 e trained in Urology in the South West of England.&nbsp\;</p>\n\n<p style=
 "box-sizing: border-box\; margin: 0px 0px 0.75rem\; color: rgb(35\, 31\, 3
 2)\; font-family: &quot\;Helvetica Neue&quot\;\, Helvetica\, Arial\, sans-
 serif\; font-size: 16px\;">After completing the Uro-oncology fellowship at
  the Department of Urological Sciences\, University of British Columbia\, 
 Vancouver\, Canada\, he spent 4 years as a Consultant Urological Surgeon a
 t the Freeman Hospital\, Newcastle upon Tyne (2014-2018).&nbsp\;</p>\n\n<p
  style="box-sizing: border-box\; margin: 0px 0px 0.75rem\; color: rgb(35\,
  31\, 32)\; font-family: &quot\;Helvetica Neue&quot\;\, Helvetica\, Arial\
 , sans-serif\; font-size: 16px\;">Jonathan was appointed to the Bristol Ur
 ological Institute (BUI)\, North Bristol NHS Trust in 2018. He specialises
  in the management of prostate and bladder cancer including robotic surger
 y and leads the uro-oncology research program at the BUI.&nbsp\;</p>\n\n<p
  style="box-sizing: border-box\; margin: 0px 0px 0.75rem\; color: rgb(35\,
  31\, 32)\; font-family: &quot\;Helvetica Neue&quot\;\, Helvetica\, Arial\
 , sans-serif\; font-size: 16px\;">Jonathan is passionate about improving p
 atient outcomes and has active research interests across the patient pathw
 ay in prostate and bladder cancer. He is the present Chair of the Somerset
 \, Wiltshire\, Avon and Gloucestershire (SWAG) Urology Cancer Clinical Adv
 isory Group\, the Clinical Lead for Cancer Genomics Research for the South
  West Genomic Medicine Service Alliance and serves as a member of the Euro
 pean Association of Urology (EAU) Section of Oncological Urology Board. He
  has previously served as the chair of the British Association of Urology 
 (BAUS) Section of Oncology.</p>\n
END:VEVENT
END:VCALENDAR